Polycystic ovarian disease: current concepts of pathophysiology and therapy.
D015068:17-Ketosteroids / Q000652:urine; D000302:Adrenal Cortex / Q000378:metabolism; D000311:Adrenal Glands / Q000378:metabolism*; D000726:Androgen Antagonists / Q000627:therapeutic use; D000735:Androstenedione / Q000096:biosynthesis; D000818:Animals; D002927:Cimetidine / Q000627:therapeutic use; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D003687:Dehydroepiandrosterone / Q000096:biosynthesis; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D007986:Luteinizing Hormone / Q000378:metabolism; D010053:Ovary / Q000378:metabolism* / Q000601:surgery; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000378:metabolism / Q000503:physiopathology* / Q000628:therapy; D013148:Spironolactone / Q000627:therapeutic use; D013739:Testosterone / Q000096:biosynthesis
D015068:17-Ketosteroids; D000726:Androgen Antagonists; D013148:Spironolactone; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D017373:Cyproterone Acetate; D002927:Cimetidine; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003534:Cyproterone